Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial

Cardiovascular Endocrinology & Metabolism · Published 2026-04-13 · Journal article · DOI 10.1097/xce.0000000000000358

Free full text

Authors (14)

Wei-Siang Chen, Ning-I Yang, Subodh Verma, Min-Hui Liu, Kun-Yi Chien, Chia-Wei Chen, Adrian Quan, Hwee Teoh, Andrew T. Yan, Kim A. Connelly, Yu-Hsiang Juan, Ching-Wen Chang, C. David Mazer, Chao-Hung Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume
15
Issue
2
Year
2026

Citation

Chen, W., Yang, N., Verma, S., et al. (2026). Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial. Cardiovascular Endocrinology & Metabolism. https://doi.org/10.1097/xce.0000000000000358

Related articles